What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis

Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta-analysis with decision curve analyses (DCA) to estimate the risk of HBVr in HBsAg-negative anti-HBc-positive patients naïve to nucleos(t)ide analogues (NAs) receiving immunosuppressive treatments.